Company profile for Aulos

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL‑2 targeting antibodies that it believes have the potential to become best-in-class treatments for s...
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL‑2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
245 Main Street Floor 12 Cambridge, Ma 02142
Telephone
Telephone
+1 (617) 294-6790
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251107006073/en/New-Phase-2-Data-for-Aulos-Biosciences-Imneskibart-Reveal-Clinical-Activity-in-Melanoma-and-Non-Small-Cell-Lung-Cancer

BUSINESSWIRE
07 Nov 2025

https://www.businesswire.com/news/home/20251003952038/en/Aulos-Bioscience-to-Present-Updated-Phase-2-Data-for-Imneskibart-AU-007-in-Melanoma-and-Non-Small-Cell-Lung-Cancer-at-40th-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting

BUSINESSWIRE
03 Oct 2025

https://www.businesswire.com/news/home/20250429960244/en/Aulos-Bioscience-Presents-New-Phase-2-Data-for-AU-007-Demonstrating-Continued-Strong-Anti-Tumor-Activity-in-Advanced-Cancers-at-AACR-Annual-Meeting

BUSINESSWIRE
29 Apr 2025

https://www.businesswire.com/news/home/20250414240962/en/Aulos-Bioscience-Doses-First-Patient-in-Phase-2-Cohort-Evaluating-AU-007-in-Combination-With-Nivolumab-for-Second-Line-Treatment-of-Melanoma

BUSINESSWIRE
14 Apr 2025

https://www.businesswire.com/news/home/20250325847497/en/Aulos-Bioscience-to-Present-Promising-Phase-2-Data-for-Novel-IL-2-Therapeutic-AU-007-in-Melanoma-at-AACR-Annual-Meeting

BUSINESSWIRE
25 Mar 2025

https://www.businesswire.com/news/home/20241127548812/en

BUSINESSWIRE
27 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty